Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its second quarter 2024 financial and operating results. The Company will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide a business update. “The second quarter was highlighted by clinical and preclinical execution alongside expanded awa